Form D · Biotechnology
Intus Biosciences, LLC
Farmington, CT · CIK 0001664615
Offering snapshot reported May 27, 2025 · SEC filing
- Reported sold
- $1.09M Offering amount: $3M
- Investors reported
- 8 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 15, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 27, 2025 | Initial | $1,089,996 | No comparison | 8 | SEC filing |
| Jul 16, 2024 | Initial | $2,000,000 | No comparison | 25 | SEC filing |
| Nov 16, 2022 | Initial | $1,050,003 | No comparison | 1 | SEC filing |
| Jul 7, 2022 | Initial | $800,000 | No comparison | 1 | SEC filing |
| Feb 3, 2022 | Initial | $250,000 | No comparison | 4 | SEC filing |
| Jan 8, 2021 | Initial | $330,000 | No comparison | 5 | SEC filing |
| May 27, 2020 | Amendment | $2,214,434 | $1,329,856vs Aug 12, 2019 | 16 | SEC filing |
| Aug 12, 2019 | Initial | $884,578 | No comparison | 16 | SEC filing |
| Dec 28, 2017 | Initial | $1,842,059 | No comparison | 10 | SEC filing |
| May 31, 2016 | Initial | $500,000 | No comparison | 1 | SEC filing |
| Jan 25, 2016 | Initial | $40,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-547155
Source: Form D, filed May 27, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Paul Denslow | Director, Executive |
| Mark Driscoll | Director |
| Donna Galluzzo | Director |
| Thomas Jarvie | Director, Executive |
| H. Mark Lunenburg | Director |
| Frank J. Marco | Director |
| William Mc Kenzie | Director |
| Alan Mendelson | Director |
| Patrick O'neill | Director |
| Daniel Wagner | Director |
| Matt Watson | Director |
| David Wurzer | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
400 Farmington Avenue
Farmington, CT, 06032
Farmington, CT, 06032